Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi
Portfolio Pulse from Vandana Singh
Japan's regulatory authority has approved Leqembi, an Alzheimer's treatment developed by Eisai Co Ltd and Biogen Inc. The approval is based on Phase 3 data from the global Clarity AD clinical trial, which showed statistically significant results and confirmed the clinical benefit of Leqembi. Eisai will conduct a post-marketing survey in all patients administered Leqembi.
September 25, 2023 | 2:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eisai's Alzheimer's treatment, Leqembi, has been approved in Japan. This could potentially boost the company's revenues.
The approval of Leqembi in Japan could lead to increased sales and revenues for Eisai.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Eisai's Alzheimer's treatment, Leqembi, has been approved in Japan. This could potentially boost the company's revenues.
The approval of Leqembi in Japan could lead to increased sales and revenues for Eisai.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Biogen, in partnership with Eisai, has received approval for its Alzheimer's treatment, Leqembi, in Japan. However, Biogen's shares are down 2.19%.
Despite the approval of Leqembi, Biogen's shares have fallen. This could be due to other factors affecting the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100